Is non‐ablative 1550‐nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single‐blinded trial in 51 patients

Our findings do not support the hypothesis of NFP providing a substantial benefit in treating melasma when compared with the lone application of a broad-spectrum sunscreen.